Patients
Our technology
The ImmTAC® platform generates a new class of bi-specific biologics that is designed to overcome the limitations of other immuno-oncology agents by combining a T cell receptor (TCR)-targeting system with an anti-CD3 effector function to activate a highly potent and specific T cell response to cancer cells.
IMCgp100, our lead ImmTAC® molecule, specifically targets the melanoma-associated antigen gp100.
Disease indications
Oncology overview
Within oncology, we are applying our ImmTAC® platform to overcome the limitations of current anti-cancer therapies to deliver:
- Potent and specific re-direction of a patient’s own T cells to kill the target cancer cells.
- Access to a pool of antigenic targets that is up to nine-fold greater than traditional antibody-based therapies.
This unique and potent mechanism of action provided by ImmTAC® molecules gives the potential to tackle diverse tumour types, including solid tumours that are characteristically immune excluded, or "cold" and thus resistant to the majority of existing immunotherapies that target activation of pre-existing immune cells. ImmTAC® molecules have been shown to convert "cold" tumours to "hot" through their T cell redirecting activity.
Beyond IMCgp100, we are continuing to apply our ImmTAC® technology to target a diverse range of cancer indications.
Uveal Melanoma
Uveal melanoma is an aggressive form of melanoma that arises from melanocytes in the uveal tract of the eye. Survival in uveal melanoma has remained largely unchanged since the early 1970s with the greatest burden in metastatic disease. Currently, there is no proven standard of care for metastatic uveal melanoma, meanwhile various therapies, including checkpoint inhibitors, are used without definitive evidence of benefit in this patient population.
IMCgp100 is designed to specifically target the melanoma-associated antigen gp100 and engages T cells to direct a potent and specific response against the cancer cells.
Clinical trial locations
Clinical trials information
We have a number of clinical trials currently recruiting patients.
Further Information
For more information on clinical trials see clinicaltrials.gov.
If you are a medical professional and require further information about Immunocore, our clinical research or clinical trials, please send an email to medicalinformation@immunocore.com.
Patients should contact their doctor for information regarding any aspect of their treatment or involvement in clinical trials.
Pipeline products
Immunocore has a robust pipeline of wholly-owned and partnered programmes
Alongside high value proprietary programmes, Immunocore has co-discovery and co-development programmes with Lilly and discovery programmes, including milestones and royalties, with Genentech, GlaxoSmithKline and MedImmune (AstraZeneca).